IDYA Stock Overview
A synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
IDEAYA Biosciences, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$37.89 |
52 Week High | US$47.74 |
52 Week Low | US$23.41 |
Beta | 0.86 |
11 Month Change | -5.28% |
3 Month Change | -7.74% |
1 Year Change | 50.90% |
33 Year Change | 61.65% |
5 Year Change | 467.22% |
Change since IPO | 238.61% |
Recent News & Updates
Recent updates
Ideaya Biosciences: Poised For Success In Bladder And Lung Cancer?
Jul 08Ideaya Biosciences Continues Its Pursuit Of 'Synthetic Lethality'
Jun 18Is IDEAYA Biosciences (NASDAQ:IDYA) A Risky Investment?
Feb 22Ideaya Biosciences: A Strong Bet In Targeted Oncology
Feb 16Analysts Are Betting On IDEAYA Biosciences, Inc. (NASDAQ:IDYA) With A Big Upgrade This Week
Nov 09Here's Why We're Not Too Worried About IDEAYA Biosciences' (NASDAQ:IDYA) Cash Burn Situation
Oct 03IDEAYA Biosciences (NASDAQ:IDYA) Is In A Good Position To Deliver On Growth Plans
Jul 04We're Not Very Worried About IDEAYA Biosciences' (NASDAQ:IDYA) Cash Burn Rate
Mar 10Here's Why We're Not Too Worried About IDEAYA Biosciences' (NASDAQ:IDYA) Cash Burn Situation
Nov 04Ideaya Biosciences: Prospects Rebound With Updated Uveal Melanoma Data
Oct 06Ideaya Biosciences slides 8.5% aftermarket on $80M stock offering
Sep 14Ideaya wins first milestone in GSK deal as cancer drug reaches clinical trials
Aug 29Analysts Have Just Cut Their IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Revenue Estimates By 6.2%
Aug 25IDEAYA Biosciences GAAP EPS of -$0.57 misses by $0.05, revenue of $11.34M beats by $4.75M
Aug 15IDEAYA, Amgen in clinical trial deal for small molecule cancer agent
Jul 27Ideaya: Next 6 Months Critical For Precision Oncology Biotech
Jun 16Analysts Are Betting On IDEAYA Biosciences, Inc. (NASDAQ:IDYA) With A Big Upgrade This Week
May 16We Think IDEAYA Biosciences (NASDAQ:IDYA) Can Afford To Drive Business Growth
Apr 12Shareholder Returns
IDYA | US Biotechs | US Market | |
---|---|---|---|
7D | -5.5% | -1.0% | 0.2% |
1Y | 50.9% | 9.7% | 17.6% |
Return vs Industry: IDYA exceeded the US Biotechs industry which returned 9.7% over the past year.
Return vs Market: IDYA exceeded the US Market which returned 17.6% over the past year.
Price Volatility
IDYA volatility | |
---|---|
IDYA Average Weekly Movement | 8.0% |
Biotechs Industry Average Movement | 10.6% |
Market Average Movement | 6.2% |
10% most volatile stocks in US Market | 14.8% |
10% least volatile stocks in US Market | 3.2% |
Stable Share Price: IDYA has not had significant price volatility in the past 3 months.
Volatility Over Time: IDYA's weekly volatility (8%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2015 | 124 | Yujiro Hata | www.ideayabio.com |
IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company’s products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability. It offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform.
IDEAYA Biosciences, Inc. Fundamentals Summary
IDYA fundamental statistics | |
---|---|
Market cap | US$3.20b |
Earnings (TTM) | -US$153.74m |
Revenue (TTM) | US$11.96m |
267.6x
P/S Ratio-20.8x
P/E RatioIs IDYA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
IDYA income statement (TTM) | |
---|---|
Revenue | US$11.96m |
Cost of Revenue | US$169.81m |
Gross Profit | -US$157.85m |
Other Expenses | -US$4.11m |
Earnings | -US$153.74m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -1.82 |
Gross Margin | -1,319.69% |
Net Profit Margin | -1,285.34% |
Debt/Equity Ratio | 0% |
How did IDYA perform over the long term?
See historical performance and comparison